Abstract
Certain anti-cancer prodrugs are subject to cytochrome P450 (CYP)-mediated metabolism and become more active. Because CYP activity may be regulated by phosphorylation via adenylyl cyclase/protein kinase A, selective adenylyl cyclase subtype activators may be utilized in future chemotherapy to regulate CYP activity as a switch in a tumor tissue-specific manner.
Keywords: Cytochrome P450, protein kinase A, adenylyl cyclase, phosphorylation, forskolin, anti-cancer drugs